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Abstract Several reports in the literature describe an
increased prevalence of polycystic ovary syndrome
(PCOS) in women with epilepsy. The possible pathogene-
sis of the association between epilepsy and PCOS is not
clear yet, and different hypotheses have been proposed:
while some authors suggest that epilepsy may affect the
hypothalamic control of reproductive function, others pro-
pose a pathogenic role of the antiepileptic drug valproate.
In this article we review the literature on the subject, and
propose a pathogenic theory in which both epilepsy and
valproate play different and significant roles in inducing
reproductive endocrine disturbances in women with
seizures.
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Epilepsy and PCOS: a long story, still controversial
The first description of an association between epilepsy
and PCOS can be traced in the literature to as early as
1904, when Spratling [1] reported that women with epilep-
sy often present with enlarged and polycystic ovaries. This
observation was apparently unnoticed by the medical com-
munity and 80 years had to pass before such problems
were mentioned again in a scientific report. It was in fact
1984 when Herzog and his group [2] published a report
describing a high frequency of polycystic ovary syndrome
(PCOS) in women with temporal lobe epilepsy (TLE), fol-
lowed by a second report in 1986 [3] describing similar
results in a larger sample of TLE women. In 1988 Bilo and
coworkers [4] reported similar findings in a smaller sam-
ple of women with idiopathic generalised epilepsy (IGE).
In 1993, nearly 10 years after Herzog’s report, Isojarvi and
coworkers [5] published a report describing a high occur-
rence of menstrual disorders and/or polycystic ovaries
and/or hyperandrogenism in women with epilepsy; in the
following years this group published many other reports
(see in [6]), always confirming their earlier findings.
Finally, because of the growing concern for specific
women’s issues in epileptology, several recent studies have
been devoted to the investigation of the reproductive
endocrine status in women with epilepsy [6].
Unfortunately, the results emerging from these studies
are widely contrasting, both with regard to the prevalence
of PCOS among women with epilepsy, which varies wide-
ly in different reports, and with regard to the possible caus-
es of this association, which have been attributed by some
authors to a disturbing effect of epilepsy on the hypothal-
amus and by others to the effects of a widely used
antiepileptic drug, sodium valproate (VPA).
In this article we will review the pathogenic theories
regarding the association between PCOS and epilepsy and will
briefly examine the data from literature regarding the preva-
lence of PCOS among women with epilepsy, with the aim of
offering some tentative conclusions on this controversial issue.
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PCOS: definition, prevalence and pathogenesis
What is PCOS? An answer to this question is of fundamental
importance before discussing the association between PCOS
and epilepsy. In the last few years a substantial uniformity
has been reached in the diagnostic criteria for PCOS, and a
National Institute of Health (NIH) Conference in 1990 stan-
dardised them, at least in the USA [7]. Table 1 summarises
the clinical and laboratory findings of the “classical”, full
blown syndrome. This complete picture, however, is far from
being the most common in women with PCOS, who most
often present with only a few of these symptoms, which can,
additionally, be differently represented at different times of
their lives. Indeed, the diagnosis of PCOS in women who
present with fewer of the classic symptoms has been the
object of considerable controversy [8], and consequently the
diagnostic standards emerging from the NIH Conference of
1990, rather than describing the complete pattern of the clas-
sical syndrome, do actually suggest the “minimal” diagnostic
criteria for PCOS: that is, the clinical/laboratory findings that
are both necessary and sufficient for the diagnosis of PCOS.
As shown in Table 2, an association of menstrual irregulari-
ties and hyperandrogenism (either clinical or biochemical)
must be present, and other causes of hyperandrogenic anovu-
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lation must be ruled out. It must be underlined that the “typ-
ical” (echographic) finding of polycystic ovaries has not been
included in the NIH minimal diagnostic criteria, having been
considered insufficient and unnecessary to make a diagnosis
of PCOS. It is in fact now universally accepted that the iso-
lated finding of polycystic ovaries should not be considered
as an abnormal feature [8], as it is described on ultrasonogra-
phy in nearly 20% of normal women [8].
In a recent workshop held in Rotterdam, the European
and American Societies of Reproductive Medicine [9] actu-
ally proposed new diagnostic criteria, which also include the
morphologic picture of polycystic ovaries. However, the new
criteria are still the object of wide discussion [10–12], and
presently the NIH criteria are still considered as the most
authoritative guideline and as such are used in papers dealing
with the diagnosis and epidemiology of PCOS.
It is worth noting that the most recent reports on PCOS
prevalence in premenopausal women, obtained following
NIH criteria for diagnosis, describe remarkably similar val-
ues, with a prevalence of 6.6% in USA [13], 6.5% in Spain
[14] and 6.8% in Greece [15]. With these prevalence values,
PCOS is considered the most frequent reproductive
endocrine dysfunction in women. However, this syndrome
involves far more than the reproductive system, as it is often
associated with reduced glucose tolerance, type II diabetes
and increased cardiovascular risk. Moreover, because of
unbalanced oestrogen secretion, women with PCOS have an
increased risk of developing endometrial cancer.
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Table 1 Clinical and laboratory findings of PCOS
Clinical data
Menstrual irregularities (oligomenorrhoea/amenorrhoea)
Hirsutism, acne, androgenic alopecia
Obesity
Laboratory data
Hyperandrogenism
Increased LH/FSH rate
LH hyperpulsatility
Hyperresponsivity of LH to GnRH
Reduced glucose tolerance/diabetes
Polycystic ovaries
Table 2 “Minimal” diagnostic criteria for PCOS (NIH Conference,
1990)
Menstrual irregularities (oligo/anovulation)
Hyperandrogenism either clinical or biochemical
Exclusion of other diseases (i.e., other known causes of female
hyperandrogenism such as congenital adrenal hyperplasia,
androgen-secreting tumours and hyperprolactinaemia)
Fig. 1 Pathogenesis of PCOS: suggested
mechanisms
GnRH receptors
Acyclic estrogen
formation
Hyperandogenism
Theca stimulation
Aromatase
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Insulin resistance
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ADRENAL ANDROGEN
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HYPOTHALAMUS
PITUITARY
OVARY
ADRENAL GLAND
FSH
LH pulses
Pituitary sensitivity to GnRH
The pathogenesis of PCOS is still poorly understood
and it is unlikely that a single mechanism can be applied to
all PCOS cases. A possible key role in pathogenesis has
been attributed by different authors to the hypothalamic-
pituitary unit, to the ovary, to the adrenal gland or, most
recently, to insulin resistance. In the end, however, all
these units do reciprocally interact in the maintenance of
laboratory and clinical alterations (Fig. 1) and it is reason-
able to suppose that different pathogenic mechanisms can
be involved in different patients.
Polycystic ovary syndrome in women with seizures:
the epilepsy theory
Between 1984 and 1988 two research groups described
overrepresentation of PCOS in three series of women with
epilepsy [2–4] (TLE in the two series from Herzog et al.
and IGE in the series from Bilo et al.). Neither group found
any significant association between occurrence of repro-
ductive endocrine disturbances and use of antiepileptic
drugs (AEDs), as most of the patients with PCOS and
epilepsy were untreated at the time of the diagnosis or had
already reported menstrual irregularities before AED ther-
apy was started.
Considering these results, both groups independently
focused their attention on the possible pathogenic mecha-
nisms linking the epileptic disorder with the development
of PCOS, and hypothesised that epilepsy itself might be
responsible of a derangement of hypothalamic function
leading to reproductive dysfunction.
How could epilepsy lead to PCOS? A possible disrup-
tive effect of epileptic disorders on hypothalamic function
has been suggested. The normal menstrual cycle is the
result of complex interacting processes among hypothala-
mus, pituitary and ovaries. A key structure is a “pulse gen-
erator” in the mediobasal hypothalamus, responsible for
rhythmic activation of hypothalamic GnRH neurons and
consequent “pulsatile” release of GnRH from their termi-
nals. The maintenance of pulsatile GnRH release within a
critical range of amplitude and frequency is essential for
normal gonadotropin secretion and therefore for normal
folliculogenesis and ovulation [16].
Seizure disorders might have a definite role in altering
the regularity of these events. Medial temporal lobe struc-
tures have extensive, reciprocal, direct connections with
hypothalamic regions that are involved in reproductive
endocrine regulation, and it is consequently possible that
paroxysmal discharges involving these areas may disrupt
normal hypothalamic-pituitary function [3]. Moreover, also
the generalised epileptic discharges that characterise IGE
may derange the normal functioning of the GnRH pulse
generator, as supported by several reports [17–19] that de-
scribe significant increases in plasma PRL and, less consis-
tently, in gonadotropins after epileptic seizures (primarily
generalised tonic-clonic and complex partial seizures).
These hormonal elevations are not due to a non-specific
stress effect nor to the intense motor activity that may
occur during seizures, but are thought to result from
spreading of paroxysmal discharges within the hypothala-
mic areas, which control pituitary reproductive hormones
[17, 18].
Further support for this theory comes from the finding
of altered luteinising hormone (LH) pulsatility in untreat-
ed women with epilepsy. As LH pulsatility in peripheral
circulation strictly reflects GnRH pulsatility in the pitu-
itary portal circulation, the study of LH pulses is nowa-
days considered the most accurate way of studying repro-
ductive endocrine function at the hypothalamic level in
humans. Our group [20] assessed the basal hormone levels
and the LH pulsatile pattern in midfollicular phase in a
group of drug-free epileptic normal cycling women, com-
pared to normal controls. No significant differences in
hormone levels were found between patients and controls;
ovulation was documented in all subjects. However, the
LH pulse frequency was significantly higher in epileptic
females. Both epileptic patients and control subjects had
normal body weight and normal menstrual and ovulatory
function; none received psychotropic or hormonal drugs or
engaged in excessive physical activity. The only difference
between patients and controls was the presence of epilep-
sy in the former group. We consequently suggested that
the abnormal LH pulsatile pattern was most probably due
to epilepsy itself, and that this epilepsy-related, subclinical
abnormality of reproductive hypothalamic function might
represent the first change leading in time to a clinically
overt endocrine dysfunction such as PCOS. Alterations in
LH pulsatility in treated epileptic patients were succes-
sively described by other groups [21–24], whose data also
indicated a possible role of seizure disorders in disrupting
LH pulsatile release.
Another report from our group [25] investigated the
relationships between gonadotropin secretion and paroxys-
mal activity. Gonadotropin secretion was monitored for a
5-h period with blood samples taken every 10 min under
continuous EEG monitoring in drug-free epileptic women
and in controls. While in control subjects secretion of LH
and follicle-stimulating hormone (FSH) showed a constant
pattern throughout the study, in epileptic women these hor-
mones showed a significant rise when paroxysmal activity
increased, once again suggesting a possible spreading of
epileptiform discharges within hypothalamic areas.
The possibility that a seizure disorder may be respon-
sible for hypothalamic dysfunction is fascinating, but quite
difficult to demonstrate. The impact of seizure disorders
on the hypothalamus is probably very complex and not
necessarily limited to the acute effects of spreading of
paroxysmal activity. Seizure disorders are accompanied
by, and in some cases probably caused by, neurotransmit-
ter imbalance possibly related to genetic factors. Central
neurotransmitters modulate brain susceptibility to
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seizures, and probably also play an important role in the
pathogenesis of human epilepsies. As many of the neuro-
transmitter systems involved in the control of the seizure
threshold are also neuroendocrine modulators for the
release of GnRH, it is reasonable to suppose that a neuro-
chemical imbalance might at the same time be responsible
for both the lowering of seizure threshold and the dysfunc-
tion of GnRH secretion [4, 20, 26]. This kind of imbalance
probably acts as a pathogenic factor independently from
actual seizure control, being only in part related to seizure
frequency.
Polycystic ovary syndrome in women with seizures:
the valproate theory
In 1993 Isojarvi and coworkers [5] reported a high occur-
rence of reproductive endocrine abnormalities in a large
series of women with epilepsy, noticing a possible rela-
tionship of this phenomenon with the use of VPA.
Actually, the possible association between VPA use and
menstrual dysfunction had already been suggested by sev-
eral earlier anecdotal reports of individual epileptic patients
or of small series of epileptic women using VPA [27–31].
However, the report from Isojarvi and coworkers was the
first to describe such problems in a large series of patients,
and was followed in the subsequent years by an impressive
series of reports from the same group, all confirming their
earlier data (see in [6]). In particular, an increased preva-
lence of polycystic ovaries, hyperandrogenism and men-
strual irregularities (not necessarily associated in the same
patient and, consequently, not necessarily giving rise to a
picture of PCOS) were described in epileptic female
patients treated with VPA significantly more often than in
controls or in patients treated with other AEDs.
Several theories have been proposed to explain the
possible pathogenic mechanisms of VPA-induced
endocrine disturbances. As VPA use has often been asso-
ciated with weight increase, in their earlier reports
Isojarvi et al. suggested that weight gain could be the
main pathogenic factor leading to reproductive endocrine
disturbances [32] in women with epilepsy, proposing that
VPA-induced obesity might lead to insulin resistance and
consequently hyperinsulinaemia, resulting in direct
and/or indirect hyperstimulation of the ovaries, hyperan-
drogenism and finally in ovarian polycystic changes.
However, further studies from the same group [33] chal-
lenged the theory that VPA-induced obesity might have a
primary role in inducing endocrine and metabolic
changes and suggested that increase of androgen produc-
tion might be the first abnormal finding originating from
VPA use in epileptic women. However, VPA-related obe-
sity is still considered to play a possible additional role in
the development of endocrine disturbances, as polycystic
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ovaries, hyperandrogenism and menstrual disorders were
more common in obese than in lean women treated with
VPA [33].
How could VPA use lead to hyperandrogenism? A pos-
sible effect on gonadotropin release, mediated by a VPA-
induced increase of GABA levels affecting GnRH secre-
tion, is considered unlikely, as VPA-treated hyperandro-
genic patients have normal LH levels [5]. Alternatively, a
direct effect of VPA on androgen formation has been sug-
gested [5]. Even though the evidence of an inhibitory
effect of VPA on testosterone metabolism is indirect and
only speculative at present, VPA is thought to inhibit the
glucoronidation of several substances [34]. Consequently,
a possible VPA-mediated inhibition of the conversion of
testosterone to oestradiol could be hypothesised, with con-
sequent increase of testosterone concentrations, arrest of
follicular maturation and development of polycystic
changes in the ovaries.
Recently, Nelson-Degrave and coworkers [35], testing
the activity of VPA on androgen biosynthesis in ovarian
theca cells isolated from follicles of normal cycling
women, suggested that VPA may increase ovarian andro-
gen biosynthesis, inducing changes in chromatin modifica-
tions (histone acetylation) that augment transcription of
steroidogenic genes. The same research group [36], in a
subsequent paper in which the gene expression profiles of
untreated normal, VPA-treated normal and untreated
PCOS theca cells were compared, reported that VPA-
induced and PCOS-induced changes in gene expression
were similar, resulting in enhancement of Akt/PKB signal
transduction in human theca cells. These important data
provide the first biochemical evidence to support a role for
VPA in the genesis of PCOS-like symptoms.
The results of all these studies are very interesting and
raise a very important point. The possibility that an effec-
tive, widely used AED may give rise to unwanted
endocrine side effects, possibly resulting in reduced fertil-
ity and increased cardiovascular risk, deserves full consid-
eration both from researchers and clinical epileptologists,
and may suggest caution in prescribing VPA in women
with epilepsy, particularly in the peripubertal period.
Polycystic ovary syndrome and epilepsy: review
of the literature
After the reports from Isojarvi and coworkers, the possible
association between PCOS and epilepsy received wide
attention from the scientific community, and research
groups from all over the world published reports describ-
ing the reproductive endocrine status of women with
epilepsy. The increasing interest in this subject was a great
opportunity to clarify the debated issues – is PCOS really
overrepresented in women with epilepsy? And if this is
L. Bilo, R. Meo: Epilepsy and polycystic ovary syndrome
true, is this overrepresentation linked to VPA use, or is it
independent from the use of this drug?
Exploring the literature: problems and pitfalls
Unfortunately, no consistency of diagnostic criteria and
diagnostic tools is found in papers dealing with occurrence
of PCOS in women with epilepsy, and consequently the
results are very often difficult to interpret and virtually
impossible to compare. Many authors still confuse the con-
cept of PCOS with that of polycystic ovaries; others still
invoke a supposed lack of uniformity of criteria for di-
agnosis of PCOS as an excuse to use personal views on
this subject, completely ignoring the results of the 1990
NIH Conference or of other authoritative guidelines.
Another frequent problem is presentation of results. Many
authors, even when performing a complete evaluation of
patients, present the results only as means of hormonal val-
ues or as percentages of abnormal findings observed in
different subgroups, without giving any information on
individual data that allow determination of the prevalence
of PCOS in the studied sample.
However, even when patients are studied individually
and information on menstrual cyclicity and androgen
assessment are given, allowing a diagnosis based on NIH
criteria, results emerging from different series are always
difficult to compare, due to methodological problems in the
collection and analysis of data. Collection of menstrual his-
tory from patients may give quite different results if
patients are keeping menstrual diaries or if they are just
recalling their menstrual pattern without a written record;
prospective study of patients with direct recording of men-
strual cyclicity over time surely gives the best results, pro-
vided that the time of observation is long enough. The use
of software specifically devoted to the collection of clinical
data over time, such as the Chronorecord software, could be
useful in these situations. In addition, definition of men-
strual irregularities is not given in all studies, and may vary
in different series, so that results might actually not be
comparable. Definition of hyperandrogenism also varies
from series to series: many studies fail to evaluate clinical
hyperandrogenism and/or the complete laboratory andro-
gen pattern. Finally, in the evaluation of ovarian morpholo-
gy the use of transabdominal or transvaginal scanning may
have different degrees of accuracy, and consequently influ-
ence the results of the investigation. MRI scanning of the
pelvis, recently proposed as a more accurate diagnostic tool
[37], is employed only in a few studies.
The wide variability observed in the characteristics of
the patient series in the different reports also gives rise to
possible inaccuracies and poor comparability of results.
Only in some of the study projects were patients enrolled
consecutively, while this is probably the best way to avoid
selection bias in a prevalence study. Patient groups in dif-
ferent reports differ widely as to the percentage of subjects
with different epilepsy types or different AED therapy;
most authors do evaluate results separately according to
therapy groups but not according to epilepsy types, which
might also be a relevant factor in influencing the endocrine
status. Moreover, due to the concern about possible side
effects of VPA on reproductive health, patients on AED
polytherapy are usually divided into subgroups depending
on the presence or absence of VPA in their therapeutic reg-
imen; this choice may lead to overlooking other possible
problems induced by other AEDs whose respective influ-
ence on the endocrine status is not investigated. Regarding
reproductive endocrine status, duration of therapy regi-
mens, age at which therapy was started, type of AEDs used
in the past, epilepsy severity and location of seizure focus
are all possible relevant factors, which vary greatly among
patients within the same series and among different series.
Finally, the small size of most patient series, especially
when divided in subgroups, is a critical factor, as specifi-
cally underlined in other review articles dealing with this
issue [38, 39].
Considering all these issues, the inconsistency of
results in the different series is not surprising. With these
limitations in mind, however, some tentative conclusions
can be proposed. For the purpose of this review, we have
compared only reports in which an estimation of preva-
lence of PCOS is possible employing NIH criteria for
diagnosis, even though in some instances we had to correct
the prevalence values given by the authors. Besides
reviewing the prevalence of PCOS, we also compared the
prevalence of menstrual irregularities, hyperandrogenism
and polycystic ovaries in the reports that give such infor-
mation, in order to have a better insight of the problem.
The relationships between endocrine disturbances and
VPA use have also been assessed.
Exploring the literature: is there an increased prevalence of
PCOS in women with epilepsy? Is this related to the use of
VPA?
Women with epilepsy seem to have a high prevalence of
menstrual disturbances [3, 4, 33, 40–46]. With the excep-
tion of the report of Murialdo et al. [41], which describes
a 10.8% prevalence of menstrual irregularities (for which
no specific definition is given in the method section), in all
the series in which such information is offered the preva-
lence of irregular menstruations, ranging from 21.8% to
56.0%, is quite higher than the 7% prevalence described in
the general population in a recent epidemiological study
[47] and is observed also in drug-free patients. Although
comparisons with the general population must be evaluat-
ed with caution, it must be stressed that a high occurrence
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of menstrual dysfunctions in women with epilepsy has
been reported for a long time [48–54]. The use of VPA
does not seem to be a relevant factor in the development of
menstrual disturbances. While the series from Isojarvi et
al. [33] reports a striking and significant difference in the
prevalence of menstrual dysfunctions between VPA
patients (59.5%) and CBZ subjects (11.4%), in the major-
ity of the other reports distribution of menstrual irregular-
ities is quite similar in different therapy groups [4, 41–45],
with prevalence in VPA patients being usually even slight-
ly lower. Besides Isojarvi, the only other series describing
a higher, but not significant, prevalence of menstrual dis-
turbances in VPA subjects is the one reported by Murialdo
et al. [40] in which, however, the VPA group includes also
CBZ patients and in which the prevalence of VPA
monotherapy is not given.
Individual data on hyperandrogenism are more rarely
given [3, 4, 33, 43–46]. Moreover, some of these reports
only offer results on hirsutism without a laboratory evalu-
ation of androgens, and are consequently hardly useful for
comparison purposes. In the reports that offer laboratory
data [3, 4, 33, 43], hyperandrogenism is usually overrepre-
sented, with a single report describing a 4.5% prevalence
[44] and all the others ranging from 15.0% to 26.0% [3, 4,
33, 43]. When a comparison among VPA users and non-
VPA users is performed [4, 33, 43–46], prevalence of
hyperandrogenism is higher in VPA patients in most
reports [33, 44–46], although not significantly.
Finally, a high prevalence of polycystic ovaries (>30%)
is reported in half of the studies [33, 43, 55, 56] in which
this finding was systematically evaluated, most of which
employed transvaginal scanning or MRI rather than trans-
abdominal scanning, which is associated with a lower
prevalence [4, 40, 41, 45]. Most reports describe a higher,
but not significant, prevalence of polycystic ovaries in
non-VPA users [4, 41, 45, 46, 55]; a significantly higher
prevalence of polycystic ovaries in VPA users is once
again observed only in Isojarvi’s series [33].
How do all these data merge regarding PCOS preva-
lence in women with epilepsy? As we have already men-
tioned, the prevalence of PCOS in the general population
is about 6.6% when NIH diagnostic criteria are employed.
For comparative purposes, we will now necessarily con-
sider only reports in which PCOS in patients with epilep-
sy is diagnosed, or may be diagnosed, using the same cri-
teria [2–4, 33, 40, 43, 44]. In most of these reports, preva-
lence of PCOS is higher than 6.6%, but shows a high vari-
ability, ranging from 12.5% to 26.0%; there is only one
report [44] in which it is considerably lower (2.3%). It
must be stressed than the highest prevalence comes from
the report [43] in which the evaluation of patients is most
careful, with assessment not only of menstrual cyclicity
but of ovulation status as well, and evaluation of both clin-
ical and laboratory hyperandrogenism. Due to the small
number of observations, the possible role of VPA in PCOS
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prevalence is difficult to evaluate if we consider only the
reports in which a NIH diagnosis can be obtained; widen-
ing our analysis to all reports [4, 33, 42–46, 55, 56] in
which prevalence of PCOS is given, even if with different
criteria, we observe that most reports describe a higher
prevalence of PCOS in VPA-treated patients [33, 44, 45,
55, 56], even though this finding is statistically significant
only in two reports [33, 56].
In summary, we can conclude that women with epilep-
sy show menstrual dysfunctions significantly more often
than the general population; this finding, which has been
known for 50 years, does not seem to be related to the use
of any AED and can be observed also in drug-free patients.
Aspecific stress, caused by a chronic disease with a strong
impact on quality of life, could play a relevant role in the
pathogenesis of menstrual irregularities. However, women
with epilepsy have also a high prevalence of polycystic
ovaries and of hyperandrogenism. As we have mentioned
earlier, the finding of isolated polycystic ovaries is not per
se abnormal and, in the absence of large prospective stud-
ies monitoring reproductive health in epileptic women
with isolated ovarian changes, there is no reason to con-
sider it as a marker of endocrine abnormality. However, its
elevated prevalence in women with epilepsy is intriguing,
and its possible meaning is worth speculating. Polycystic
changes are not specifically linked to the use of VPA in
most series describing epileptic women and are frequently
observed also in drug-free epileptic patients; for this rea-
son, they seem to be related to the epileptic disorder rather
than to AED therapy. However, both the finding of hyper-
androgenism and the specific endocrine disorder of PCOS,
with its well known impact on fertility and on cardiovas-
cular health, are more frequently observed in epileptic
women using VPA. Finally, the prevalence of PCOS in
women with epilepsy is elevated in the majority of reports,
even though there is considerable variability between
series.
Polycystic ovary syndrome in non-epileptic women
treated with valproate: settling the controversy
Recently, valuable help in settling the issue of the patho-
genic mechanisms of PCOS overrepresentation in women
with epilepsy has come from researchers who have evalu-
ated the endocrine status in women receiving VPA for
bipolar disorders, thus examining the effect of VPA sepa-
rately from that of epilepsy.
The reports from O’Donovan et al., presented in a con-
gress abstract [57] and then in a full report [58], display
several shortcomings, which warrant caution in the inter-
pretation of the results. To begin with, there are several dif-
ferences between the results displayed in the congress pre-
sentation and those given in the full report, up to the point
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that the conclusions are completely contrasting; as there
are only minimal changes in the patient population
between the two reports, it is difficult to explain such con-
trasting results. Information about menstrual irregularities
and hyperandrogenism was obtained only from a self-
reported questionnaire, and only patients who received
VPA and had current menstrual abnormalities underwent a
clinical and laboratory evaluation and could be diagnosed
as having PCOS. However, no valid comparison is possi-
ble on this point with non-VPA bipolar patients, who were
not submitted to any clinical or laboratory study. Finally,
the pathogenic relationship between the endocrinological
disturbance and the use of VPA remains to be proved, as
the authors themselves underline that a temporal associa-
tion between VPA use and clinical disturbances is lacking
in several cases. For a more detailed analysis of these
reports, we suggest a consultation of more extensive
reviews on the subject [6, 59].
Rasgon et al. [60] evaluated the endocrine status of 80
bipolar women (in a previous pilot study the evaluation
was limited to 22 subjects [61]) treated with VPA (alone or
in association) or with other antimanic agents. Prevalence
of PCOS in the total group of bipolar patients was 5%,
specifically with 8% prevalence in VPA patients and 0% in
non-VPA patients; when considering only PCOS cases
with onset after VPA treatment, prevalence was 6% in the
VPA group and 0% in the non-VPA group. We can con-
clude that prevalence of PCOS in bipolar patients does not
differ from prevalence in the general population; it is (not
significantly) higher in VPA users, but again with values
only slightly different from the general population. In
addition, bipolar women in this series showed a very high
prevalence of menstrual abnormalities, often preceding the
use of antimanic drugs but with a considerable increase
after medication. This was true especially after VPA use.
These disturbances, however, were most often limited to
altered bleeding patterns (menorrhagia) while disturbances
in menstrual cyclicity (oligomenorrhoea and amenorrhoea)
consistent with ovulatory disorders and PCOS were less
represented. The same group [62] recently reported a 2-
year longitudinal evaluation in 25 women with bipolar dis-
order, treated with VPA, lithium or atypical antipsychotics,
confirming high rates of menstrual abnormalities, hyper-
androgenaemia and insulin resistance in the whole group.
Valproate use was associated with an increase in total
testosterone over time, but rates of oligomenorrhoea and
clinical hyperandrogenism did not differ between medica-
tion groups.
In the report from McIntyre et al. [63], describing 38
bipolar female patients treated with VPA or lithium, men-
strual irregularities and hyperandrogenism were, when
considered separately, significantly more represented in
VPA women than in lithium patients. PCOS prevalence
was also higher in the VPA group (39% vs. 19%), but not
significantly; on the whole, these results – in disagreement
with those from Rasgon’s group – show a very high preva-
lence of PCOS in bipolar patients, especially in VPA users,
but with high values also in the lithium group.
Akdeniz et al. [64] compared the endocrine status of
women with epilepsy and women with bipolar disorder,
describing 15 bipolar patients treated with lithium, 15 bipo-
lar patients treated with VPA and 15 epileptic patients treat-
ed with VPA. Menstrual irregularities were observed in
46.7% of the VPA-treated epileptic women, 20% of the VPA-
treated bipolar women and 0% of the lithium-treated bipolar
women. Laboratory hyperandrogenism was observed in both
VPA groups but not in the lithium group; however, only in
women with epilepsy was this finding associated with hir-
sutism. The authors conclude that even though VPA treat-
ment is associated with raised testosterone levels in both
bipolar and epileptic women, the latter have an increased
susceptibility to clinical endocrine dysfunction.
Finally, in a very recent report Joffe et al. [65] evaluat-
ed 230 women with bipolar disorder, comparing the inci-
dence of self-reported oligoamenorrhoea with hyperandro-
genism that developed after antimanic treatment.
Oligoamenorrhoea with hyperandrogenism developed in 9
(10.5%) of 86 women on valproate and in 2 (1.4%) of 144
women on other treatments (p=0.002), suggesting a signif-
icant association of PCOS with VPA use in bipolar women.
Consequently, the authors suggest that VPA use rather than
epilepsy per se could be responsible for overrepresentation
of PCOS in epileptic women as well. The authors under-
line that the percentage of women developing PCOS fea-
tures on VPA is much lower in their study than that report-
ed in many of the studies describing epileptic populations
[5, 56] and attribute this difference mainly to the fact that
these studies have not utilised accepted criteria for the
diagnosis of PCOS. However, there are also studies on
epileptic populations in which well accepted criteria for
diagnosis of PCOS have been employed [43] and in which
a considerably higher percentage of women with epilepsy
(26%) were diagnosed with PCOS, without a significant
association with the use of VPA. However, the report of
Joffe et al. is specifically focused on patients with new-
onset of PCOS symptoms developed after medication use,
and consequently reports incidence of PCOS rather than
prevalence. Consequently, caution must be employed in
comparing the results from this study to those coming
from studies describing prevalence.
In conclusion, bipolar patients seem to show an
increased risk of developing endocrine disturbances or
PCOS when treated with VPA in respect to other antiman-
ic medications. However, in most reports on this issue
prevalence of PCOS in VPA-treated bipolar patients is
lower than that reported in epileptic patients. One could
speculate that the impact of VPA on endocrine status is not
as strong in bipolar patients as in women with epilepsy,
suggesting that these latter may have additional risk fac-
tors leading to the development of PCOS.
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Conclusions: different roles of epilepsy and VPA in
development of PCOS
The association between epilepsy and PCOS is still a
debated issue [66]. Based on the finding of abnormal LH
pulsatility in drug-free, endocrinologically normal epilep-
tic women reported in our previous study [20], we pro-
posed [20, 26] that a derangement of the GnRH pulse gen-
erator might be observed in women with epilepsy, caused
by spreading of paroxysmal activity within the hypothala-
mus and/or by neurotransmitter dysfunctions, which ac-
company seizure disorders; this abnormal finding is inde-
pendent from AED use, may be observed in normally ovu-
lating epileptic women and does not necessarily lead to
clinical reproductive endocrine disturbances. The possible
evolution towards a clinical dysfunction is probably
dependent on several different additional factors, whose
relative importance may be difficult to evaluate (Fig. 2). As
a result of this increased susceptibility to hypothalamic
dysfunction, a high percentage of women with epilepsy
will present with menstrual disorders, and, possibly, poly-
cystic ovaries. The further possible evolution towards a
definite clinical disease, specifically PCOS, seems con-
versely to be more often related to the use of AEDs, and in
particular of VPA. This VPA effect is most probably due to
its hyperandrogenic activity, recently demonstrated in vitro
on human theca cells; weight gain, often associated with
VPA use, may also play an additional role. In fact, even
though obesity is not considered as a prerequisite in the
development of PCOS, weight gain may act as a modifier
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that might contribute to the genesis and maintenance of
hyperandrogenic chronic anovulation [8].
Sommario Diverse evidenze in letteratura suggeriscono
che nelle donne con epilessia vi sia un’aumentata preva-
lenza di Sindrome dell’Ovaio Policistico (PCOS). Peraltro
la possibile patogenesi di questo fenomeno non è ancora
chiarita, e, mentre alcuni autori suggeriscono che l’epiles-
sia di per sé disturbi il controllo ipotalamico della funzio-
ne riproduttiva, altri propongono che il farmaco antiepilet-
tico valproato sia determinante nell’indurre la disfunzione
endocrino riproduttiva. Questo articolo esamina la vasta
letteratura sull’argomento e propone una teoria patogene-
tica unificatrice, in cui sia l’epilessia che l’uso del val-
proato giocano ruoli diversi e rilevanti nel determinismo
della PCOS delle pazienti con epilessia.
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